NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 241 filers reported holding NOVOCURE LTD in Q3 2019. The put-call ratio across all filers is 0.53 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $2,432,579 | +74.0% | 33,164 | +80.3% | 0.10% | +65.6% |
| Q3 2022 | $1,398,000 | +575.4% | 18,396 | +1867.5% | 0.06% | +916.7% |
| Q2 2021 | $207,000 | -96.0% | 935 | -96.9% | 0.01% | -96.7% |
| Q4 2020 | $5,138,000 | +47.9% | 29,692 | -4.9% | 0.18% | +16.9% |
| Q3 2020 | $3,474,000 | +90.4% | 31,213 | +1.4% | 0.15% | +75.0% |
| Q2 2020 | $1,825,000 | -9.5% | 30,782 | +2.8% | 0.09% | -32.8% |
| Q1 2020 | $2,017,000 | -90.8% | 29,957 | -88.5% | 0.13% | -87.3% |
| Q4 2019 | $22,021,000 | +19.3% | 261,315 | +5.9% | 1.04% | +8.5% |
| Q3 2019 | $18,458,000 | -29.1% | 246,835 | -40.0% | 0.95% | -31.6% |
| Q2 2019 | $26,029,000 | +36.4% | 411,659 | +3.9% | 1.40% | +28.9% |
| Q1 2019 | $19,083,000 | +71.3% | 396,158 | +19.1% | 1.08% | +32.9% |
| Q4 2018 | $11,138,000 | -61.3% | 332,667 | -39.4% | 0.81% | -50.9% |
| Q3 2018 | $28,785,000 | +74.5% | 549,328 | +4.2% | 1.66% | +58.6% |
| Q2 2018 | $16,497,000 | – | 527,055 | – | 1.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 470,884 | $27,923,000 | 10.09% |
| Darsana Capital Partners LP | 1,700,000 | $100,810,000 | 5.98% |
| HARTLINE INVESTMENT CORP/ | 336,617 | $19,961,000 | 4.18% |
| Rhenman & Partners Asset Management AB | 375,000 | $22,238,000 | 2.40% |
| MORGAN JESS S & CO INC | 35,942 | $2,131,000 | 2.31% |
| Soleus Capital Management, L.P. | 56,397 | $3,344,000 | 1.91% |
| Bullseye Asset Management LLC | 45,161 | $2,678,000 | 1.43% |
| Taylor Frigon Capital Management LLC | 46,304 | $2,746,000 | 1.36% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $593,000 | 1.09% |
| Redwood Investments, LLC | 192,986 | $11,444,000 | 1.01% |